Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Alnylam Pharmaceuticals Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Alnylam Pharmaceuticals's (NASDAQ:ALNY) reported sales totaled $213.26 million. Despite a 7.01% increase in earnings, the company posted a loss of $240.34 million. Alnylam Pharmaceuticals collected $258.54 million in revenue during Q4, but reported earnings showed a $258.46 million loss.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.